Inventor · disambiguated record
Catherine Rougeot
Also filed as: COUTINHO ANTONIO · ROUGEOT CATHERINE
18 granted patents·10 pending applications·124 citations·filing 1997–2016
94Inventor score
Top patents by PatentIndex Score
28 records- 0188US7625713B2Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptidePASTEUR INSTITUT·Filed 2006·Granted Dec 1, 2009·10 cites·5 claims
- 0284US6713617B2Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogensPASTEUR INSTITUT·Filed 2000·Granted Mar 30, 2004·15 cites·5 claims
- 0383US7153833B2Therapeutic uses of SMR1 peptidesCENTRE NAT RECH SCIENT·Filed 2001·Granted Dec 26, 2006·14 cites·35 claims
- 0480US7423020B2Treatment of mood disorders by administration of SMR1PASTEUR INSTITUT·Filed 2001·Granted Sep 9, 2008·10 cites·5 claims
- 0576US8017571B2Peptides derived from human BPLP proteinPASTEUR INSTITUT·Filed 2005·Granted Sep 13, 2011·3 cites·9 claims
- 0676US7387778B2Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disordersPASTEUR INSTITUT·Filed 2001·Granted Jun 17, 2008·9 cites·14 claims
- 0775US6589750B2Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivativesPASTEUR INSTITUT·Filed 1997·Granted Jul 8, 2003·32 cites·6 claims
- 0873US9403871B2Methods for treating pain by administering peptides derived from human basic proline-rich lacrimal proteinPASTEUR INSTITUT·Filed 2014·Granted Aug 2, 2016·2 cites·16 claims
- 0972US8889827B2Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidasesROUGEOT CATHERINE·Filed 2009·Granted Nov 18, 2014·1 cites·17 claims
- 1072US8642729B2Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidasesROUGEOT CATHERINE·Filed 2009·Granted Feb 4, 2014·1 cites·23 claims
- 1170US8895251B2Method for detecting human BPLP protein or a maturation product thereofROUGEOT CATHERINE·Filed 2011·Granted Nov 25, 2014·2 cites·12 claims
- 1267US2010041072A1Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptidePASTEUR INSTITUT·Filed 2009·Application pending·0 cites
- 1365US7851603B2Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogensCENTRE NAT RECH SCIENT·Filed 2006·Granted Dec 14, 2010·0 cites·6 claims
- 1465US7732563B2Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogensPASTEUR INSTITUT·Filed 2006·Granted Jun 8, 2010·0 cites·7 claims
- 1564US6818405B2Therapeutic use of the SMR1 protein and active derivatives thereofPASTEUR INSTITUT·Filed 1998·Granted Nov 16, 2004·15 cites·57 claims
- 1662US9273094B2Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidasesPASTEUR INSTITUT·Filed 2014·Granted Mar 1, 2016·0 cites·24 claims
- 1760US2005130166A1Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogensPASTEUR INSTITUT·Filed 2003·Application pending·0 cites
- 1860US2011178021A1Opiorphin for use as a psychostimulant agentPASTEUR INSTITUT·Filed 2009·Application pending·0 cites
- 1960US2005090656A1Cloning, sequencing and expresssion of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogensPASTEUR INSTITUT·Filed 2003·Application pending·0 cites
- 2059US2009298109A1Method for identifying bplp and opiorphin agonists or antagonistsPASTEUR INSTITUT·Filed 2009·Application pending·0 cites
- 2158US8168770B2Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogensMINOPRIO PAOLO·Filed 2006·Granted May 1, 2012·0 cites·15 claims
- 2258US7429448B2Therapeutic use of the SMR1 protein and active derivatives thereofPASTEUR INSTITUT·Filed 2003·Granted Sep 30, 2008·10 cites·28 claims
- 2356US2012034604A1Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarkerROUGEOT CATHERINE·Filed 2009·Application pending·0 cites
- 2455US9714951B2Pharmaceutical compositions containing peptides derived from human BPLP proteinPASTEUR INSTITUT·Filed 2016·Granted Jul 25, 2017·0 cites·29 claims
- 2550US2014193843A1Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarkerROUGEOT CATHERINE·Filed 2014·Application pending·0 cites
- 2650US2003186870A1Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disordersFiled 2002·Application pending·0 cites
- 2742US2015329608A1Opiorphin for use as a psychostimulant agentPASTEUR INSTITUT·Filed 2015·Application pending·0 cites
- 2832US2003195155A1Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivativesPASTEUR INSTITUT·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Catherine Rougeot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →